478 related articles for article (PubMed ID: 23620425)
1. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study.
Yu F; Liu X; Zhong Y; Guo X; Li M; Mao Z; Xiao H; Yang S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3385-93. PubMed ID: 23620425
[TBL] [Abstract][Full Text] [Related]
2. [Protection effect of sodium hyaluronate on ocular surface toxicity induced by Benzalkonium chloride-preserved brimonidine in rabbits].
Yu FF; Liu X; Zhong YM; Mao Z; Guo XX; Li M; Cao D; Chen XX
Zhonghua Yan Ke Za Zhi; 2013 Nov; 49(11):973-80. PubMed ID: 24512997
[TBL] [Abstract][Full Text] [Related]
3. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions.
Liang H; Brignole-Baudouin F; Riancho L; Baudouin C
Ophthalmic Res; 2012; 48(2):89-101. PubMed ID: 22473057
[TBL] [Abstract][Full Text] [Related]
4. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride.
Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819
[TBL] [Abstract][Full Text] [Related]
5. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
Kahook MY; Noecker RJ
Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation.
Pauly A; Roubeix C; Liang H; Brignole-Baudouin F; Baudouin C
Invest Ophthalmol Vis Sci; 2012 Dec; 53(13):8172-80. PubMed ID: 23150620
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications.
Liu X; Yu FF; Zhong YM; Guo XX; Mao Z
Chin Med J (Engl); 2015 Sep; 128(18):2444-9. PubMed ID: 26365960
[TBL] [Abstract][Full Text] [Related]
8. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models.
Liang H; Baudouin C; Daull P; Garrigue JS; Buggage R; Brignole-Baudouin F
Cornea; 2012 Nov; 31(11):1319-29. PubMed ID: 22929154
[TBL] [Abstract][Full Text] [Related]
10. The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.
Pellinen P; Huhtala A; Tolonen A; Lokkila J; Mäenpää J; Uusitalo H
Curr Eye Res; 2012 Feb; 37(2):145-54. PubMed ID: 22049909
[TBL] [Abstract][Full Text] [Related]
11. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study.
Pisella PJ; Debbasch C; Hamard P; Creuzot-Garcher C; Rat P; Brignole F; Baudouin C
Invest Ophthalmol Vis Sci; 2004 May; 45(5):1360-8. PubMed ID: 15111589
[TBL] [Abstract][Full Text] [Related]
12. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.
Liang H; Baudouin C; Pauly A; Brignole-Baudouin F
Br J Ophthalmol; 2008 Sep; 92(9):1275-82. PubMed ID: 18723745
[TBL] [Abstract][Full Text] [Related]
13. Changes in rabbit corneal innervation induced by the topical application of benzalkonium chloride.
Chen W; Zhang Z; Hu J; Xie H; Pan J; Dong N; Liu Z
Cornea; 2013 Dec; 32(12):1599-606. PubMed ID: 24113372
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost.
Baudouin C; Riancho L; Warnet JM; Brignole F
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4123-8. PubMed ID: 17724196
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.
Brignole-Baudouin F; Riancho L; Liang H; Baudouin C
Curr Eye Res; 2011 Nov; 36(11):979-88. PubMed ID: 21999224
[TBL] [Abstract][Full Text] [Related]
17. Corneal and conjunctival changes caused by commonly used glaucoma medications.
Noecker RJ; Herrygers LA; Anwaruddin R
Cornea; 2004 Jul; 23(5):490-6. PubMed ID: 15220734
[TBL] [Abstract][Full Text] [Related]
18. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study.
Labbé A; Pauly A; Liang H; Brignole-Baudouin F; Martin C; Warnet JM; Baudouin C
J Ocul Pharmacol Ther; 2006 Aug; 22(4):267-78. PubMed ID: 16910868
[TBL] [Abstract][Full Text] [Related]
19. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells.
Guenoun JM; Baudouin C; Rat P; Pauly A; Warnet JM; Brignole-Baudouin F
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2444-50. PubMed ID: 15980234
[TBL] [Abstract][Full Text] [Related]
20. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
